The Research Is Not Complete

This website focuses on the medication categories with the strongest published evidence of lasting neurological harm: SSRIs, SNRIs, benzodiazepines, antipsychotics, Accutane, fluoroquinolones, and finasteride. These are the drugs where peer-reviewed research, FDA warnings, and patient reports have accumulated to a point that the evidence cannot reasonably be dismissed.

But the absence of a dedicated page on this site does not mean a medication is safe. It means the research is either insufficient, too early, or simply hasn't been done yet. The history of every drug covered here followed the same pattern: decades of patient reports dismissed as anecdotal, followed by research that confirmed what those patients had been saying all along.

Medications That Need More Attention

Tricyclic Antidepressants (TCAs)

Tricyclic antidepressants were among the first antidepressants developed, introduced in the 1950s and widely prescribed before SSRIs became the dominant class. Common TCAs include amitriptyline (Elavil), nortriptyline (Pamelor), clomipramine (Anafranil), imipramine (Tofranil), desipramine (Norpramin), and doxepin. They work by inhibiting the reuptake of both serotonin and norepinephrine, but also affect histamine, acetylcholine, and adrenergic receptors, which accounts for their broad side effect profile.

TCAs carry well-documented risks including cardiac arrhythmias, anticholinergic effects (dry mouth, constipation, urinary retention, blurred vision), sedation, weight gain, cognitive impairment, and sexual dysfunction. They are particularly dangerous in overdose, with a narrow margin between therapeutic and lethal doses. Withdrawal from TCAs can produce severe discontinuation symptoms including nausea, headache, malaise, insomnia, and rebound depression. Clomipramine, in particular, has been associated with severe protracted withdrawal syndromes and seizures. Despite being older drugs, TCAs are still widely prescribed for chronic pain, migraines, insomnia, and OCD, often without adequate informed consent about risks or withdrawal potential.

Atypical Antidepressants

"Atypical antidepressants" is a catch-all category for antidepressants that don't fit neatly into the SSRI, SNRI, or TCA classes. They include bupropion (Wellbutrin), mirtazapine (Remeron), trazodone, nefazodone, vortioxetine (Trintellix/Brintellix), vilazodone (Viibryd), and agomelatine. Each works through a different mechanism, and each carries its own distinct risk profile.

Bupropion (Wellbutrin) is a norepinephrine-dopamine reuptake inhibitor (NDRI) prescribed for depression, smoking cessation, and ADHD. It carries a dose-dependent risk of seizures and has been associated with psychosis, severe agitation, and lasting sexual dysfunction in some patients. Mirtazapine (Remeron) is commonly prescribed for depression and insomnia due to its sedating effects, but patients report significant weight gain, severe withdrawal symptoms, and protracted discontinuation syndromes. Trazodone is one of the most widely prescribed sleep medications despite being an antidepressant, and withdrawal can be significant after long-term use. Vortioxetine (Trintellix) is a newer serotonin modulator that has been associated with serotonin syndrome and discontinuation effects similar to SSRIs.

Because these drugs are often prescribed as "alternatives" to SSRIs and SNRIs, patients and prescribers sometimes assume they are safer or have fewer withdrawal risks. Patient reports suggest otherwise. Many individuals in our blog stories describe harm from atypical antidepressants alongside or independent of other psychiatric medications.

Gabapentin & Pregabalin (Gabapentinoids)

Originally developed as anticonvulsants, gabapentinoids have become some of the most widely prescribed medications in the world — for everything from nerve pain to anxiety to off-label sleep disorders. Reports of severe protracted withdrawal syndromes, cognitive impairment, and neurological damage after discontinuation are growing rapidly in patient communities. Gabapentin prescriptions have exploded in recent years, partly as doctors sought alternatives to opioids, yet the withdrawal potential and long-term neurological risks remain poorly studied and rarely disclosed to patients.

Dopamine Agonists

Prescribed for Parkinson's disease, restless legs syndrome, and hyperprolactinemia, dopamine agonists (pramipexole, ropinirole, cabergoline) are associated with severe impulse control disorders — compulsive gambling, hypersexuality, binge eating, and compulsive spending — that can devastate lives before the drug is ever suspected. Withdrawal can trigger Dopamine Agonist Withdrawal Syndrome (DAWS), an underrecognized condition involving severe anxiety, panic, depression, and suicidal ideation that can persist for months or years.

Vaccines

While vaccines have prevented enormous amounts of disease, the rate at which they're administered to children and babies hasn't properly been studied. An unknown subset of individuals experience severe and lasting adverse reactions that are well-documented but rarely discussed. The U.S. government's own Vaccine Adverse Event Reporting System (VAERS) and the National Vaccine Injury Compensation Program (VICP) — which has paid out over $4.7 billion in claims — exist precisely because vaccine injuries are real and recognized at the federal level. Reported injuries include Guillain-Barré syndrome, transverse myelitis, chronic inflammatory demyelinating polyneuropathy (CIDP), autoimmune conditions, myocarditis, and severe neurological damage. Patients who report these injuries are frequently dismissed or accused of being "anti-vaccine," creating a chilling effect that discourages reporting and suppresses the true incidence. The 1986 National Childhood Vaccine Injury Act granted vaccine manufacturers broad legal immunity from liability — meaning injured patients cannot sue manufacturers directly and must instead navigate a specialized federal compensation program. This legal shield, combined with aggressive cultural stigma against questioning vaccine safety, means that the gap between patient experience and acknowledged harm may be wider here than with any other category of medical product.

Topical & Oral Steroids

Corticosteroids are among the most commonly prescribed drugs in medicine, dispensed for everything from eczema and asthma to autoimmune conditions and inflammation. Both the topical and oral forms carry well-documented risks of severe and lasting harm that are rarely discussed at the point of prescription.

Topical steroids (hydrocortisone, betamethasone, clobetasol, triamcinolone, and others) are routinely prescribed for skin conditions, often for months or years on end. After prolonged use, a subset of patients develop Topical Steroid Withdrawal (TSW), also known as Red Skin Syndrome — a debilitating condition characterized by burning, oozing, peeling, and severe inflammation that can cover the entire body and last for years after the medication is stopped. The National Eczema Association now formally recognizes TSW, and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) issued an official safety warning in 2021. Despite this, most dermatologists still do not warn patients about the risk before prescribing.

Oral and systemic steroids (prednisone, prednisolone, dexamethasone, methylprednisolone) can trigger steroid-induced psychosis, severe mood disturbances, mania, depression, suicidal ideation, insomnia, and anxiety — sometimes from a single short course. Long-term use is associated with adrenal insufficiency, Cushing's syndrome, osteoporosis, avascular necrosis, cataracts, diabetes, and muscle wasting. Withdrawal from oral steroids, even after relatively short courses, can precipitate adrenal crisis, profound fatigue, joint pain, and a constellation of withdrawal symptoms that are often dismissed as the original condition returning. Patients are frequently tapered too quickly or not warned about the need for tapering at all.

And More

Other medications generating concerning reports of severe or lasting harm include certain anticonvulsants (topiramate, lamotrigine), hormonal contraceptives, proton pump inhibitors, statins, and various immunosuppressants. In each case, the gap between patient experience and published research follows a familiar and troubling pattern.

Why This Matters

The medications documented in detail on this site were once considered safe too. Patients who reported lasting harm were told it was impossible, that the symptoms were psychological, that they needed more medication. It took decades of suffering and advocacy before the research community acknowledged what was happening — and in many cases, that acknowledgment is still incomplete.

If you have experienced severe or lasting effects from any medication not covered on this site, your experience matters. The absence of research does not invalidate what you are going through. It means the medical establishment has not yet caught up.